Lack of activity of amphotericin B in systemic murine fusarial infection

Area of Science:

• Mycology
• Infectious Diseases
• Cancer Research

Background:

• Systemic fusarial infections are increasingly recognized as a critical cause of mortality in immunocompromised individuals, particularly cancer patients.
• Effective management strategies for these infections remain poorly understood.
• Fusarium species exhibit known resistance to conventional antifungal therapies.

Purpose of the Study:

• To evaluate the in vivo antifungal activity of amphotericin B against disseminated fusarial infections.
• To determine the efficacy of amphotericin B in prolonging survival and clearing infection in a murine model.

Main Methods:

• CF1 mice were infected with two pathogenic strains of Fusarium solani.
• Amphotericin B was administered intraperitoneally at daily doses of 0.5, 1, and 2 mg/kg for up to 10 days.
• Survival rates and fungal burden in kidneys were assessed.

Main Results:

• Amphotericin B treatment did not significantly prolong the survival of infected mice at any tested dose.
• Clearance of Fusarium solani from the kidneys was comparable between mice treated with 1 mg/kg/day of amphotericin B and untreated control animals.
• These findings align with established in vitro and in vivo resistance of Fusarium species to amphotericin B.

Conclusions:

• Amphotericin B demonstrates limited efficacy in treating disseminated fusarial infections in this murine model.
• The study underscores the challenges in managing Fusarium infections, especially in cancer patients.
• Further research into alternative antifungal agents is warranted for Fusarium infections.